UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues

Keyphrases

• Ritonavir 100%
• Efavirenz 100%
• Mouse Tissue 100%
• High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS) 100%
• Indinavir 100%
• Mouse Serum 100%
• Atazanavir 100%
• Antiviral Drugs 50%
• Pharmacokinetics 25%
• Lung 25%
• Liver 25%
• AIDS/HIV 25%
• Antiretroviral Therapy 25%
• Methanol 25%
• Preclinical Development 25%
• Kidney 25%
• Dynamic Range 25%
• Biological Fluids 25%
• Therapeutic Agents 25%
• Tissue Distribution 25%
• Biological Tissue 25%
• Mass Spectrometer 25%
• Sustained Release 25%
• Spleen 25%
• Therapeutic Regimen 25%
• Mobile Phase 25%
• Lopinavir 25%
• Human Immunodeficiency Virus Infection 25%
• Acetonitrile 25%
• Chromatographic Separation 25%
• Ammonium Acetate 25%
• Targeted Release 25%
• UPLC™ 25%
• Linear Quadrupole Ion Trap 25%
• Negative Ionization Mode 25%
• Electrospray Ionization Source 25%
• RP-18 25%
• NanoART 25%
• Drug Quantification 25%
• Fold Increase 25%
• 4-fold 25%
• MS Method 25%
• Combination ART 25%

Chemistry

• Tandem Mass Spectrometry 100%
• Ritonavir 100%
• Indinavir 100%
• Atazanavir 100%
• Efavirenz 100%
• Antiretroviral 75%
• Pharmacokinetics 25%
• Methanol 25%
• Electrospray Ionization 25%
• Mobile Phase Composition 25%
• Chromatography 25%
• Area Under the Curve 25%
• Ultra Performance Liquid Chromatography 25%
• Ion Trap 25%
• Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry 25%
• Acetonitrile 25%
• Quadrupole 25%
• Ammonium Acetate 25%
• Lopinavir 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Efavirenz 100%
• Indinavir Plus Ritonavir 100%
• Atazanavir 100%
• Atazanavir Plus Ritonavir 50%
• Anti-Human Immunodeficiency Virus 25%
• Sustained Release 25%
• Ultra High Performance Liquid Chromatography 25%
• Methanol 25%
• Human Immunodeficiency Virus Infection 25%
• Lopinavir 25%
• Acetonitrile 25%
• Ammonium Acetate 25%
• Electrospray Ionization 25%
• Pharmacokinetics 25%